Abstract. Drug release from hydrophilic matrices is regulated mainly by polymeric erosion, disentanglement, dissolution, swelling front movement, drug dissolution and diffusion through the polymeric matrix. These processes depend upon the interaction between the dissolution media, polymeric matrix and drug molecules, which can be significantly influenced by formulation variables and excipients. This study utilized mathematical parameters to evaluate the impacts of selected formulation variables and various excipients on the release performance of hydrophilic polyamide 6,10 (PA 6,10) monolithic matrix. Amitriptyline HCl and theophylline were employed as the high and low solubility model drugs, respectively. The incorporation of different excipient concentrations and changes in formulation components influenced the drug release dynamics as evidenced by computed mathematical quantities (t x% , MDT x%, f 1 , f 2 , k 1 , k 2 , and К F ). The effects of excipients on drug release from the PA 6,10 monolithic matrix was further elucidated using static lattice atomistic simulations wherein the component energy refinements corroborates the in vitro and in silico experimental data. Consequently, the feasibility of modulating release kinetics of drug molecules from the novel PA 6,10 monolithic matrix was well suggested.
INTRODUCTION
The significance of hydrophilic polymer-based monolithic matrices as carriers for rate-modulated drug release has been on the increase as evidenced by the number of published manuscripts, patents and their applications in producing new commercially available drug products (1) (2) (3) . To an extent, the prevalent and successful use of hydrophilic polymeric drug delivery systems can be associated with their ease of manufacturing, broad acceptance by the US Food and Drug Administration, relatively low cost of production, satisfactory in vivo performance and flexibility in controlling the release of drugs with a broad range of physicochemical properties (1) (2) (3) . Common hydrophilic polymers such as gelatin, hydroxypropylmethylcellulose, xanthan gum, hydroxpropylcellulose, polyethyleneoxide, polyvinyl alcohols, carbopol, and alginate that are employed in the formulation of monolithic matrices for controlled drug delivery have been extensively investigated (2) (3) (4) (5) (6) (7) .
Research has shown that drug release from hydrophilic monolithic matrices is mainly controlled by polymer erosion, disentanglement, dissolution and/or swelling front movement as well as drug dissolution and diffusion through the polymer matrix at the molecular level (2, 3, 8) . These phenomena depend upon the interaction between the dissolution media, polymeric matrix and drug (3) and are influenced by several formulation variables, which include but are not limited to the drug concentration, drug solubility, polymer particle size (5, (8) (9) (10) , drug to polymer mass ratio, polymer viscosity, polymer molecular mass (3, 4, 10) and the addition of different types and levels of formulation excipients (1, (11) (12) (13) (14) (15) .
Polyamide 6,10 (PA 6,10) is a hydrophilic even-even configured, poly-condensed, synthetic aliphatic polyamide. Synthetic aliphatic polyamides have found applications in drug delivery applications as multiple-unit systems such as microcapsules (16, 17) , hollow fibers (18) , gelospheres (19) and monolithic matrices (20, 21) . In addition, they have been known to possess pertinent physical properties such as thermal and abrasion resistance, chemical inertness, high physicomechanical strength, hydrophilicity, a high level of purity after production and controlled matrix dissolution (17, 18, (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) that makes the polyamides attractive for use in drug delivery. Generally, polyamides can be described as non-toxic and biocompatible, which stems from their extensive clinical use as both absorbable and nonabsorbable surgical sutures (35) (36) (37) (38) (39) (40) .
The present study attempts to explore the effects of formulation variables and excipients on the drug release dynamics of a PA 6,10-based monolithic matrix employing a mathematical analytical approach. Monolithic matrices fabricated from synthesized PA 6,10 have been previously investigated, and their potential to function as matrices for rate-modulated drug release was established (20, 21) . Nevertheless, to the best of our knowledge, no scientific report relating the impact of formulation variables and excipients to the drug delivery characteristics of these unique delivery systems have been published. This is of particular importance since changes in formulation variables may further modulate the established drug release performance of the matrices and possibly broaden its drug delivery applicability. Therefore, this investigation focuses on establishing the influences of relevant formulation variables and excipients on the drug release performance from a PA 6,10 monolithic matrix. Amitriptyline hydrochloride (100% water soluble at 25°C) (41) and theophylline (0.85% water soluble at 25°C) (41) were respectively employed as model high and low solubility drugs in this study.
EXPERIMENTAL SECTION Materials
Hexamethylenediamine (M w =116.2 g/mol), sebacoyl chloride (M w =239.1 g/mol), cyclohexane, anhydrous n-hexane, anhydrous sodium hydroxide pellets, amitriptyline HCl and theophylline were purchased from Sigma Chemical Company (St. Louis, USA Preparation of the PA 6,10-Based Monolithic Matrices PA 6,10 was synthesized using modified interfacial polymerisation reaction previously described by Kolawole et al. (20) . Each monolithic matrix comprised of a physical mixture of powdered PA 6,10 (300 mg) (particle size, 711-1,000 μm) and 50 mg of either of the model drugs with or without the respective formulation excipients throughout the study unless otherwise stated. Thorough mixing of the respective solids was carried out for about 15 min using a laboratory scale blender (CG 100, Kenwood Ltd., Cambridge, UK). Final blends were compressed into flat-surfaced, cylindrical monolithic matrices each having an average diameter of 13±1 mm and thickness of 4±1 mm using a Beckman hydraulic press (Beckman Instruments, Inc., Fullerton, USA) under a pressure of 1 ton, except stated, for 60 s.
Influence of Variations in Formulation Variables on the Drug
Release Characteristics from the PA 6,10 Matrices
Selection of Model Drugs and Composition of Comparative Control Formulation
For the assessment of the impact of polymer-drug ratio, force of compaction, polymeric particle size and formulation excipients, amitryptiline hydrochloride was selected as the model drug because of its high water solubility, which makes it more suitable for determining the controlled release capability of the PA 6,10 monolithic matrix. However, theophylline and amitryptiline hydrochloride were employed as models for visualising the effects of drug solubility on the release characteristics of the PA 6,10 monolithic matrix. The control formulation (CF) for all the ensuing comparative experiments was made up of 300 mg PA 6,10 (particle size, 711-1,000 μm) and 50 mg of either model drug compressed at 1 ton. The impact of drug solubility on the release behaviour of the PA 6,10 monolithic matrix was assessed using 50 and 150 mg each of either amitryptiline hydrochloride or theophylline, respectively. The composition of each formulation employed to assess the effects of varying the polymer-drug mass ratio on drug release behaviour are presented in Table I . Different magnitudes of compaction forces ranging from 2.0, 3.0 and 4.0 tons were utilised for fabricating the matrices comprising 50 mg of amitryptiline hydrochloride and 300 mg PA 6,10. Textural analysis was used to determine the indentation hardness, which was computed as the Brinell hardness number (BHN). The BHN was used as a measure of matrix hardness or resistance to physicomechanical deformation due to an external compression force applied. A calibrated Texture Analyzer (TA.XTplus, Stable MicroSystems, Surrey, England) fitted with a ball probe of diameter 3.125 mm was employed for determining the peak force generated after indentation. The parameter settings employed were pre-test (2 mm/s), test (0.5 mm/s) and post-test (10 mm/s) speeds; trigger force (2 g); load-cell (5 kg); and indentation diameter of 1.563 mm. Data was captured at a rate of 200 points per ) was calculated using Eq. 1.
Impacts of Variations in
where F=force generated from indentation (N), D=diameter of ball probe indenter (3.125 mm) and d=indentation diameter (1.563 mm). The impact of polymeric particle size was determined utilising laboratory test sieves (Endecotts Ltd, London, UK) with aperture sizes of 710 μm, 1.00 mm and 1.20 mm, which equates to particle size ranges of 1-710 μm, 711-1,000 μm (control) and 1,001-1,200 μm.
Effects of Alternative Polymers and Inorganic Excipients on the Release Dynamics of the PA 6,10 Monolithic Matrices
The influence of alternative polymers on drug release from the monolithic matrices was assessed using specific quantities of a mixture of PA 6,10 with PLGA or HPMC or PEO to prepare a monolithic matrix as stated in Table I .
The influence of inorganic electrolytes on drug release from the PA 6,10 monolithic matrices was explored utilising PA 6,10 blended with either K 2 SO 4 or MgSO 4 or Al 2 (SO 4 ) 3 (Table I) .
Dissolution Studies
In vitro dissolution studies were performed on each set of monolithic matrix to investigate the influence of the abovementioned modulators on release kinetics. Each formulation was placed in a calibrated six-station dissolution testing apparatus (Caleva Dissolution Apparatus, model 7ST) using the standard USP 25 rotating paddle method at 50 rpm with 500 mL phosphate-buffered saline (PBS) (pH 7.4; 37±0.5°C). Five hundred milliliters PBS was used because no specific physiological condition was explored and also both model drugs, the electrolytes and alternative polymers as well as PA 6,10 dissolved sufficiently in it. The dissolution apparatus was modified by including a stainless steel ring mesh contrivance to prevent the hydrated formulation from floating (42) . For the determination of the model drug concentration, 5 mL samples were withdrawn and filtered through a 0.45 μm pore size Cameo Acetate membrane filter (Millipore Co., Bedford, Massachusetts, USA) at specific time intervals over a period of 24 h. Samples were then analyzed by ultraviolet spectroscopy (Specord 40, Analytik Jena, AG) at 240 nm (amtryptiline hydrochloride) or 270 nm (theophylline). An equivalent volume to the quantity withdrawn of drug-free PBS was replaced into the dissolution medium to maintain sink conditions. A correction factor was appropriately applied in all cases where dilutions of samples were required, and all measurements were done in triplicate.
Treatment of Dissolution Data
With reference to the nature of this study, mathematical expressions were applied to facilitate thorough comparison and evaluation of the generated drug release data.
Model Independent Analyses
The explanation of the dissolution profiles using model independent methods encompassed the computation of specific dissolution quantities and fit factors discussed in the following sub-sections.
Time Point Approach
With this approach, t x% (time required to release a specific amount of drug) values and mean dissolution times (MDT) set at MDT x% (mean dissolution time of a specific amount of drug released) were computed. The application of t gives the specific time at which a certain amount of drug is released, while the MDT provides a more accurate view of the drug release behaviour as it is determined as the sum of the individual periods of time during which a specific fraction of the total drug dose is released (42) (43) (44) . Equation 2 was employed in the calculation of the MDT.
where M t is the fraction of dose released in time t i , t i =(t i +t i−1 )/ 2, and M ∞ corresponds to the loading dose.
Fit Factors
Fit factors comprise of difference (f 1 ) and similarity components (f 2 ) (Eqs. 3 and 4) (1, 42, (45) (46) (47) (48) . These parameters compare and establish similarities and differences between two dissolution curves obtained from a set of experimental data (47) . For this study, the f 2 component was utilised to evaluate selected drug release profiles (Eq. 3). When two profiles are similar, f 2 values range from 50 to 100 while f 2 <50 indicate that the profiles are not similar (1, 42) .
where R t is the reference assay at time point t, T t is the test assay at time point t, n is the number of pull points (or time points) and w t is an optional weight factor.
Model Dependent Analysis

Kinetic Models
Usually, drug release from hydrophilic polymer based delivery systems have been described with the mechanisms of matrix relaxation and Fickian diffusion, which take place concurrently and are considered summative to the overall release performances (2, 49) . The well-known Peppas and Sahlin empirical model describes the abovementioned phenomenon. It is an expanded version of the power law, which functions irrespective of the geometry of the drug delivery device (Eq. 4).
where k 1 is the Fickian diffusion kinetic constant and k 2 is the relaxational or erosion rate constant, m is a kinetic constant and Q=M t /M ∞ is the fractional or percentage drug released in time, t (2,12,50,51). Generated dissolution data was fit into the Peppas and Sahlin model using Guassian-Newton approach for all least squares analyses on the WinNonlin Professional Edition, Version 5 (Pharsight, USA) and Sigma Plot, Version 11, (Systat Software Inc., California, USA).
Application of a Second-Order Polynomial Equation
The intrinsic values of fraction of drug released obtained at each time point was fitted into a second-order polynomial equation from which the fractional release rate constant (К F in fraction/hour) was computed as the summative gradient for each profile. This parameter provided concise information as regards the drug release performances of the respective formulation under study and was useful for comparison of the dissolution profiles. All fitted curves were validated using the correlation coefficient, R 2 (values between 0.8 and 1 were considered relevant). In addition, the correlation factor (r), and p values were determined when necessary to assess the degree of relationship amongst data sets and level of linearity, respectively. The Sigma Plot, Version 11 software (Systat Software Inc., California, USA) was employed. Outcomes were presented as mean±standard deviation (SD).
Establishment of the Complexation Profile and Drug Release Mechanism via Static Lattice Atomistic Simulations
Computational modeling including energy minimisations in Molecular Mechanics was performed using HyperChem™ 8.0.8 Molecular Modeling Software (Hypercube Inc., Gainesvi lle, Flori da, U SA) and ChemBio3D Ultra 11.0 (CambridgeSoft Corporation, Cambridge, UK). The threedimensional (3D) structures of PA 6,10 (mPA), PLGA and PEO were archetyped using ChemBio3D Ultra in their syndiotactic stereochemistry, whereas the structure of HPMC (4 saccharide units) was built from standard bond lengths and angles using the Sugar Builder Module on HyperChem 8.0.8. The models were primarily energy-minimised using the MM+ force field algorithm and resulting structures subjected to energy minimisation using the Assisted Model Building and Energy Refinements 3 (AMBER 3) force field algorithm. The conformer having the lowest energy was used to develop the mPA-excipient and mPA-electrolyte complexes. A complex of one polymer molecule with another was assembled by parallel disposition and energy minimisation was repeated to generate the molecular complex models. Full geometrical optimisation was conducted in vacuum employing the Polak-Ribiere conjugate gradient method until a RMS gradient of 0.001 kcal/mol was reached (52) . To generate the final models in solvated system, mPA-PLGA, mPA-HPMC, mPA-PEO, mPA-Al, mPA-K and mPA-Mg, simulations were performed for cubic periodic boxes with the polymer/polymer at the center of the cubic box and the remaining free space filled with water molecules. Energy minimisation was repeated to generate the solvated models except that the force fields were utilised with a distance-independent dielectric constant with no scaling (Table II) . Additionally, the force field options in the AM-BER (with explicit solvent) were extended to incorporate cutoffs to inner and outer options with the nearest-image periodic boundary conditions, which were applied to ensure that there were no discontinuities in the potential surface (Table II) (53) .
RESULTS AND DISCUSSION
Impact of Formulation Variables on the Drug Release Characteristics of the PA 6,10 Monolithic Matrices
Solubility of Incorporated Model Drugs
Drug release profiles generated by the PA 6,10 monolithic matrices were comparable irrespective of the differences in solubilities of the loaded model drugs (r=0.998) at a 15% (50 mg) drug loading level (f 2 ≥50≤100) (Table III ). An increase in drug loading to 35% (150 mg) showed a significant (p<0.05) difference (r=0.435) in the profiles in which case drug solubility had an influence on release rate (f 2 <50). This was justified by determining the f 2 values at five dissolution time points (t 1 h , t 6 h , t 12 h , t 18 h and t 24 h ) for each formulation (Table III) . The dissolution profile generated for amitryptiline HCl was selected as reference while that of theophylline was the test and vice versa (Fig. 1) .
Drug release from the PA 6,10 monolithic matrices at 15% drug loading can be said to be comparatively independent of drug solubility but mainly regulated by PA 6,10 matrix hydration or disentanglement. Nevertheless, the formulation containing amitryptiline HCl released slightly higher drug concentrations than that with theophylline at each time point (Table III) . The influence of drug solubility on the release behaviour of the PA 6,10 matrix was more visible with an increase in drug loading to 35%. Overall, the release of amitryptiline HCl from PA 6,10 was faster than that of theophylline, and this pattern appeared to be more noticeable with an increase in drug concentration. This may be attributable to the higher hydrophilicity of amitryptiline HCl compared with theophylline ( Fig. 1) . Amitryptiline HCl enhanced outward influx of the dissolution medium resulting in the rapid dissolution and diffusion of drug molecules from the matrix, while theophylline possibly displayed an opposite behaviour because of its lower solubility by increasing the matrix stiffness and hydrophobicity resulting in slower drug release kinetics.
Variation in Polymer Mass and Drug Ratios
The differences in the composition of the respective formulations had a considerable impact on the drug release dynamics and the discrepancies were further substantiated with the MDT x% values. The MDT 10% and MDT 30% values were selected based on the fact that these dissolution points were common to all generated profiles (Fig. 2) . An elevation or decline in the MDT values respectively indicated an increase or decrease in the duration required for a certain quantity of drug to be released.
A decrease in polymer concentration as exemplified with formulations 1, 2 and 3, resulted in an increase in drug release substantiated with the computed MDT 10% (0.083, 0.051 and 0.029 h) and MDT 30% (1.383, 0.951 and 0.108 h), respectively when compared to the control (MDT 10% =0.099 h; MDT 30% = 1.570 h). An increase in burst levels, measured at t 1 h (12%, 20% and 35%, respectively) was observed with a decrease in PA 6,10 relative to the control (t 1 h =7%). This can be attributed to the reduction in drug diffusion path length as a result of the reduction in polymer concentration. Consequently, the matrix is more susceptible to the impacts of hydration and disentanglement after the absorption of water molecules resulting in a quicker rate of drug diffusion. Formulations 4 and 5, containing a higher PA 6,10 concentration, displayed a decrease in drug release rates and burst levels (MDT 10% =0.125 and 0.194 h; MDT 30% =2.25 h and 3.245 h; t 1 h = 6%, 4%) when compared with the control (MDT 10% =0.099 h; MDT 30% =1.570 h; t 1 h =7%). This may be as a result of an extension of the diffusion path length related to the increased polymer concentration. Furthermore, the trends observed for the release profiles of formulations 1-5 can be associated with their varying degrees of matrix permeability associated with the porosity levels of the respective matrices. In instances where polymeric concentration was reduced (formulations 1-3), the matrix upon hydration could be highly permeable with a low degree of tortuosity, minimal matrix strength, rapid erosion and quicker outward migration of drug molecules from the matrix while the reverse is the case when polymer concentration is higher (3). The PA 6,10 matrix demonstrated the potential to regulate drug release kinetics as formulation 3, which was composed of the lowest polymer concentration displayed the most rapid and irregular release pattern while formulation 5 with the highest polymer concentration showed the slowest, most consistent release characteristics (Fig. 2) .
Profiles produced from formulations 6-9 displayed the effects of drug concentration on the PA 6,10 matrix. Generally, when compared to the control (MDT 10% = 0.099 h; MDT 30% =1.570 h; t 1 h =7%), an increase in drug concentration within the matrix amplified the release rates and bursteffects. Formulation 8 with the highest concentration of amitryptiline HCl elicited the most rapid drug release rate which was quantified by a lower MDT 10% and MDT 30% values (0.011 and 0.047 h, respectively). These outcomes were further substantiated by the elevated level of burst-effects of 47% determined at t 1 h . On the contrary, formulation 9 contained the lowest amount of drug demonstrated a slower, more regulated release rate confirmed by the higher MDT 10% and MDT 30% (0.118 and 2.646 h, respectively) and a burst level at (6%). The observed pattern may be due to the ability of the hydrophilic amitryptiline HCl molecules to either increase or decrease the water uptake potential within the matrix as the drug loading levels increased or decreased respectively with the consequential effect of intensifying or minimising the velocities of matrix hydration, relaxation, dissolution and drug diffusion. Likewise, as drug loading increased (formulations 6-8), the release performance of the PA 6,10 matrices was by matrix dissolution and drug diffusion. Thus, more water molecules were absorbed into the monolithic matrices, which probably enhanced the formation of continuous, intra-matrix interconnections that may have resulted in the formation of open pathways facilitating the outward diffusion of drug molecules while an opposite trend is expected at lower drug levels (formulation 9) (Table I , Fig. 2b ).
Application of Different Forces of Compaction
Table IV outlines the changes in the magnitude of the measured mathematical quantities resulting from varying the applied force of compaction. A sequential increase in compression force from 1, 2, 3 and 4 t decreased the quantity of drug released over time. The observed changes in the drug release characteristics may be associated with an increase in the magnitude of inter-and intra-particulate electrostatic forces of attraction/cohesion amongst the polymer-polymer, drug-drug and/or polymer-drug particles as a result of the increase in the force of compaction. These proposed interactions can influence the packing capacity of the monolithic matrix resulting in an increased magnitude of the particulate cohesive interactions thereby enhancing matrix compactness and reduction in the rate of influx of water molecules into the matrix, thus retarding the rate of matrix wetting, extrication, dissolution, erosion and drug release. The t x% values fixed at common dissolution points of t 10% and t 25% were employed to further corroborate the abovementioned propositions. An elevation in the force of compression from 1 (control) to 2-4 tons (as 4 tons was the maximum force that could be attained with the Beckman hydraulic press employed) of the had a significant (p=0.0001) elevating impact on the level of matrix hardness quantified by the BHN and t x% values (Table IV) . In other words, the differences in the BHN numerical values were vital measures for the degree of matrix firmness dependent on the magnitude of the forces of compression.
Influence of Polymeric Particle Sizes
The changes in PA 6,10 particle sizes considerably modulated release performance as an increase in particle size decreased the amount of drug released over time, while the reverse was the case for a decrease in particle size (Fig. 3 ). The reduction in particle size appeared to increase the surface area and wettability of the polymer and drug. Consequently, the water-absorbing capacity was impacted, thus making the hydrated more porous as a result of a reduced degree of tortuosity related to smaller particle size. However, with larger polymeric particle size, the extent of matrix wetting was reduced as the level of tortuosity may be higher leading to a minimised rate of disentanglement and diffusion of drug and a slower rate of drug release. 
Elucidating the Influence of Formulation Excipients on Drug Release Kinetics
Alternative Hydrophobic and Hydrophilic Polymeric Compounds
The inclusion of formulation excipients caused noteworthy disparities in exhibited drug release trends of the PA 6,10 matrix (Fig. 4) . The most distinct release profile was that of formulation 10, which elicited a marked decrease in the amount of drug released over time when compared with the control formulation. This may be associated with the hydrophobic nature of PLGA, which implies that the hydrophilicity of PA 6,10 within the matrix was noticeably lessened. Generally, a slight but significant (p=0.035) dissimilarity was observed between the matrix containing HPMC and the control. However, HPMC, due to its hydrophilic nature, minimally enhanced the water-absorbing capacity of the matrix resulting in a slight elevation in the quantity of drug released (Fig. 4) . In addition, this minimal impact of HPMC inclusion on release behaviour with reference to the control may be due to the capability of HPMC to undergo extensive dimensional swelling caused by an increase in viscosity during matrix wetting. This influenced the polymeric free volume and constituted a mechanism that HPMC employs to modulate drug release from the matrix (4,7,13,54,55) . Furthermore, the matrix composed of PEO generated profiles showing increase in the amount of drug released over time. The hydrophilic nature of PEO as well as its minimal swelling tendencies, which can enhance and stabilise drug release velocities, respectively, could also have served as a contributing factor to the drug release behaviour.
Besides the above-mentioned propositions, drug release profiles were separately fitted into the Peppas and Sahlin mathematical model to assess the contributions of the polymeric additives to the diffusional and relaxational phases of drug release from the PA 6,10 matrix by computing k 1 (% h -0.43 ) and k 2 (% h -0.86 ), respectively (2,7). For this investigation Q≤65.55% and t=24 h were employed for the respective formulations. In addition, m=0.43 was employed as it was the most appropriate for the geometry (aspect ratio) of monolithic matrix systems being investigated as previously established by Durig and Fassihi (Eq. 4) (2).
With reference to the total duration of drug release, the profiles can be considered linear (R 2 >0.90≤1.00; formulations 10, , and this can still be associated with hydrophobic tendencies of PLGA. Conversely, the presence of HPMC and PEO increased the diffusional and relaxational release constants. The values generated for PEO were slightly higher (k 1 =14.899% h ). Essentially, the polymeric excipients influenced the diffusional and relaxational components of the overall process of drug release over 24 h and therefore modulated the release kinetics of the drug molecules from the PA 6,10 matrix.
Impact of Ionisable Inorganic Electrolytes
The inclusion of inorganic electrolytes played distinctive roles in modulating the release of drug from the PA 6,10 matrix. A relationship between the drug release and the valency of the cationic and anionic components of the electrolyte was observed (Fig. 5) . The inorganic electrolytes minimised the overall quantity of drug released over time compared with the control. This was further substantiated by the computed fractional release rate constant, К F , values. Formulation 15, containing cations with the highest valency (Al 3+ ), had the slowest release rate (К F =0.009 fraction released/h) while formulation 13 containing the electrolyte with the lowest cationic valency (K + ) showed a Fig. 3 . Diverse impact of PA 6,10 particle size variation on the drug release behaviour from the PA 6,10 monolithic matrices (n=3 and standard deviation≤0.08 in all cases) Furthermore, the pattern demonstrated by the electrolytes can be related to the phenomena proposed by Durig and Fassihi (2) as well as Pillay and Fassihi (13) , which explained that a vital competitive interaction can exists between electrolyte and water species within a matrix system on exposure to the dissolution media during hydration. Consequently, the unionised electrolyte competes with the polymeric matrix for water species at the outset of influx. Therefore, the electrolyte, if more hydrophilic than the polymeric matrix attracts some of the water molecules within the matrix to dissociate into ionic components. This initial competition for water for hydration dehydrates the polymer matrix leading to suppression of initial polymeric wetting preceding drug diffusion. However, once sufficient water for hydrolysis has been attracted by the electrolyte within matrix microenvironment, the solubilised electrolyte species undergo an efflux process that possesses the potential to create porous channels within the hydrated matrix for the penetration of more water molecules, which then enhances polymeric matrix hydration, progressive matrix relaxation and outward drug diffusion.
With reference to the drug release characteristics demonstrated by the electrolytes included in the PA 6,10 matrix and the abovedescribed phenomenon, it can therefore be proposed that the valency of the ions that constitute the test formulations influenced the interaction between the water molecules, polymeric components and respective electrolyte. This determined the extent of hydration based on the amount of water molecules required by each electrolyte for complete matrix hydrolysis into their ionic moieties. Furthermore, a competition between PA 6,10 and the respective electrolytes for water molecules may have occurred within the monolithic matrix. Based on the semicrystalline nature of PA 6, 10 (28) , the affinity of the electrolytes for water can outweigh that of PA 6,10 since the electrolytes are more crystalline and hydrophilic in nature. Therefore, the electrolytes set the pace with regards to the velocity of water infiltration into the respective matrices, and this subsequently influenced the rate of hydration of the polymeric matrix and ultimately the drug release efficiencies.
Hypothetically, it can be proposed that the higher the values of the cationic charges/charge densities (Al 3+ ), the greater the quantity of water molecules required to bring about a complete hydration and ionisation of the respective electrolyte species. This implied that there can be more competition for water molecules between the electrolyte and the polymeric component. Consequently, a higher level of polymeric dehydration is expected for matrices containing electrolyte species of this sort. This results in the suppression of drug release, as the process of polymeric matrix wetting which leads to breaking up of polymer chains leading to drug release was initially deactivated. At the point when sufficient water had been attracted by the electrolyte species for complete hydration and ionisation, then the ionised species can migrate out of the matrix creating considerable fissures within the matrix for water penetration, which can enhance matrix hydration, unfolding and drug release. For matrices containing cations with lower valences (K  + and Mg   2+ ), the intensity of competition with the polymer for water molecules was milder because the amount of water required for complete hydration and ionisation was less. Therefore, the polymeric matrix was less dehydrated, and some level of hydration, disentangling and diffusion was initiated before the completely hydrated electrolyte species began to migrate out of the matrix to create more channels for water penetration that further enhanced drug release. 
Effect of Polymeric Excipients
The component energy values related to mPA-PLGA, mPA-HPMC and mPA-PEO are shown in Table V , while the respective geometrically stabilised 3D conformations are displayed in Fig. 6 . The mPA-PEO was most stabilised among the three mPA-excipient complexes with a total steric energy of ≈−3,092 kcal/mol as compared to ≈−2,895 kcal/mol and ≈−2316 kcal/mol for mPA-HPMC and mPA-PLGA, respectively (Table V) . Interestingly, the stabilised energies for mPA-PEO and mPA-HPMC were close in magnitude, and this relates very well with the similarity between their drug release profiles (Fig. 4) . A faster drug release from mPA-PEO and mPA-HPMC may be attributed to the increased stabilisation of the complex in the vicinity of water molecules→increased affinity towards water→enhanced hydrophilicity of the matrix→increased access to the diffusion of water molecules into the matrix→higher drug release. An inverse relationship was observed for the mPA-PLGA formulation wherein the rate of drug release was reduced due to well-known hydrophobicity of PLGA. The polymer-excipient structures were mainly stabilised by the electrostatic interactions and hydrogen bonding component and were destabilised by all bonding energies (angle, bond and torsion energies) as well as the van der Waals forces. Conclusively, the non-bonding interactions balanced the torsional strain created by the bonding forces to accommodate the most feasible geometrical conformation as shown in Fig. 6 .
Effect of Inorganic Electrolytes
The component energy values related to mPA-Al, mPA-K and mPA-Mg are shown in Table V , and the respective geometrically stabilised 3D conformations are displayed in Fig. 7 . It is evident from Table V that mPA-Al was most stabilised among the three mPA-electrolyte complexes with a total steric energy of ≈−2,059 cal/mol as compared to ≈−1,982 kcal/mol and ≈−1951 kcal/mol for mPA-Mg and mPA-K, respectively. Interestingly, the stand-out stabilisation of mPA-Al supports the experimentally observed much slower drug release from F15 [Al 2 (SO 4 ) 3 ] as compared to F13 (K 2 SO 4 ) and F14 (MgSO 4 ) represented by mPA-K and mPA-Mg, respectively (Fig. 5) . A slower drug release from more stabilised mPA-Al can be attributed to the increased stabilisation of the complex in the vicinity of water molecules→increased ionisation of the metal ion→increased cross-linking of the matrix structure→suppression of the initial polymeric wetting→slower drug release. The inverse is true for mPA-K and mPA-Mg formulations wherein the drug release rate was faster than mPA-Al due to a lesser amount of cross-linking prevailing in the monovalent and divalent crosslinked systems. Another reason for a slower drug release from mPA-Al may be attributed to hydrogen bonding (V hb =−3.127; Table V) prevailing within the matrix leading to the formation of a well-knit polymer architecture, which was absent in the case of mPA-Mg and mPA-K molecular structures (Fig. 7) . Similar to polymer-excipient complexes, the polymer-electrolyte structures were mainly stabilised by the electrostatic interactions and were destabilised by all bonding energies (bond, angle and torsion energies) as well as by the van der Waals forces.
CONCLUSIONS
In this study, the significant effects of formulation variables and excipients on the drug release performances of the novel PA 6,10-based monolithic matrix were investigated. The observed impacts revealed the robust and flexible, yet rate-modulated drug release behaviour and kinetics of the PA 6,10 matrix system, which resulted in the compilation of applicable deductions. Furthermore, the relevance of reputable mathematical expressions in assessing and comparing dissolution data as well as establishing the various possible drug release mechanisms of the PA 6,10 monolithic matrix was ascertained. The in silico lattice simulations for mPA-excipient and mPA-electrolyte complexes complemented the experimentally observed drug release profiles.
